You searched for "legislation"
The inflammatory side-effect of Brimonidine
Brimonidine is a well established selective alpha-2 adreno-receptor agonist, used to lower intraocular pressure. This case series reports on 19 eyes affected by brimonidine induced uveitis. Mean age of the patients was 74 years and mean duration of brimonidine use...
Allergic eyelid dermatitis
This is a retrospective 12 year review of 61 patients diagnosed with periocular allergic dermatitis. The average age was 66 years, with 74% being female. The commonest indications for referral were epiphora, ectropion and blepharitis; and the main symptoms were...
A phase 3 randomised trial of nicotinamide for skin cancer chemoprevention
To B3, or not to B3? That was the question asked in this controlled trial in which the authors were able to show that oral nicotinamide (vitamin B3) is able to reduce further skin cancer development in high risk patients....
Antibiotic prophylaxis after intravitreal injections
The use of topical antibiotics as prophylaxis after intravitreal injections is a contentious issue, especially now with increasing use of intravitreal anti-VEGF agents. In the Wills Eye Institute, prior to May 2011, all patients undergoing intravitreal injections in the office...
Medical treatment of orbital lymphatic malformations
This is a literature review of the use of Sirolimus, to treat orbital lymphatic malformations. Sirolimus is an immunosuppressant used in renal transplants, and acts by inhibiting mammalian target of rapamycin (mTOR), which in turn inhibits activation of T and...
How does low-concentration atropine reduce progression of myopia?
This is a double-blind, randomised, placebo-controlled trial evaluating the effects of low-concentration atropine (0.05%, 0.025%, 0.01%) on ocular biometrics of myopic children. The aim is to determine what aspect of ocular biometrics low-concentration atropine influenced in reducing the progression of...
Myopia progression with atropine and different treatment lenses
This study aimed to determine the effectiveness of low dose atropine at inhibiting myopia progression, the possible additive potency of this treatment combined with either of two peripheral defocus contact lenses over three years of therapy, and whether there was...
Profile of presentation, follow-up and management of orbital myositis
This retrospective study reviewed the demographic characteristics of patients with orbital myositis, their clinical profile, management options, outcomes and predictive factors for recurrence. The study included 52 patients (55 eyes; 3% bilateral involvement), 36 females, with mean age at presentation...
How many injections in nAMD: ranibizumab vs. aflibercept
Intravitreal anti-VEGF injections make up a large proportion of the workload in ophthalmology clinics. Since the introduction of aflibercept with eight weekly injections there has been an option to use a treatment which may require less treatment, with potential cost...
Ranibizumab for the treatment of age-related macular degeneration
This multicentre randomised prospective open label study compared 0.5 versus 2mg of ranibizumab in patients with submacular retinal pigment epithelial (RPE) detachment due to age-related macular degeneration. Four treatment regimens were used for the two strengths either monthly for 12...
Detection of antiranibizumab antibodies in exudative AMD
In this study the authors aimed to detect immune response to ranibizumab treatment in wet age-related macular degeneration (AMD). An ELISA was employed to quantify the anti-ranibizumab titre which was compared against the control anti-abciximab titre. Titres of anti-ranibizumab antibodies...
